Article

The role of cholinergic system in neuronal plasticity: focus on visual cortex and muscarinic receptors

Institute of Neuroscience (C.N.R.), 56100 Pisa, Italy.
Archives italiennes de biologie (Impact Factor: 1.42). 10/2008; 146(3-4):165-88. DOI: 10.4449/aib.v146i3.767
Source: PubMed
Download full-text

Full-text

Available from: Luciano Domenici, Apr 01, 2014
0 Followers
 · 
87 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The modulation of gamma power (25-90 Hz) is associated with attention and has been observed across species and brain areas. However, mechanisms that control these modulations are poorly understood. The midbrain spatial attention network in birds generates high-amplitude gamma oscillations in the local field potential that are thought to represent the highest priority location for attention. Here we explore, in midbrain slices from chickens, mechanisms that regulate the power of these oscillations, using high-resolution techniques including intracellular recordings from neurons targeted by calcium imaging. The results identify a specific subtype of neuron, expressing non-α7 nicotinic acetylcholine receptors, that directly drives inhibition in the gamma-generating circuit and switches the network into a primed state capable of producing high-amplitude oscillations. The special properties of this mechanism enable rapid, persistent changes in gamma power. The brain may employ this mechanism wherever rapid modulations of gamma power are critical to information processing. Copyright © 2015 the authors 0270-6474/15/350761-16$15.00/0.
    The Journal of Neuroscience : The Official Journal of the Society for Neuroscience 01/2015; 35(2):761-75. DOI:10.1523/JNEUROSCI.4001-14.2015 · 6.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This experiment examined the effects of mecamylamine, a nicotinic acetylcholine receptor antagonist, on flash-evoked potentials (FEPs) recorded from the visual cortex (VC) and superior colliculus (SC) of chronically implanted male Long-Evans rats, and on body temperature and open field behavior. FEPs were recorded at 20 and 35 min following intraperitoneal injections of saline, and of 0.3, 3.0, and 10.0 mg/kg mecamylamine on separate days. The 0.3 mg/kg dose did not produce significant effects. The amplitude of VC components N₃₀, P₄₈, and P₈₇ increased, N₁₅₀ and P₂₃₁ decreased, and P₂₃, N₄₀, N₅₈, and N₆₈ were unchanged following administration of the 10.0 mg/kg dose. In the SC, component P₂₈ was unaffected, P₃₉ was reduced, and N₄₉ was augmented by the 10.0 mg/kg dose. All component peak latencies were increased by the 3.0 and 10.0 mg/kg doses. Significant hypothermia was also produced by the 3.0 and 10.0 mg/kg doses, suggesting that this was the basis for the increased latencies. The 10.0 mg/kg dose produced a significant decrease in movement during the recording sessions. In subsequent open field observations, both line crossings and rearings were reduced by the 3.0 and 10.0 mg/kg doses. The results suggest that endogenous acetylcholine acting on nicotinic acetylcholine receptors plays at most a modest role in producing FEPs recorded from the VC and SC.
    Pharmacology Biochemistry and Behavior 02/2011; 97(4):660-8. DOI:10.1016/j.pbb.2010.11.015 · 2.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Previously we demonstrated that mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate], a representative of the aza-butyrobetaine class of compounds, protects mitochondrial metabolism under conditions such as ischemia. Mildronate also acted as a neuroprotective agent in an azidothymidine-induced mouse model of neurotoxicity, as well as in a rat model of Parkinson's disease. These observations suggest that mildronate may stimulate processes involved in cell survival and change expression of proteins involved in neurogenic processes. The present study investigated the influence of mildronate on learning and memory in the passive avoidance response (PAR) test and the active conditioned avoidance response (CAR) test in rats. The CAR test employed also bromodeoxyuridine (BrdU)-treated animals. Hippocampal cell BrdU incorporation was then immunohistochemically assessed in BrdU-treated, CAR-trained rats to identify proliferating cells. In addition, the expression of hippocampal proteins which could serve as memory enhancement biomarkers was evaluated and compared to non-trained animals' data. These biomarkers included glutamic acid decarboxylase 65/67 (GAD65/67), acetylcholine esterase (AChE), growth-associated protein-43 (GAP-43) and the transcription factor c-jun/activator protein-1 (AP-1). The results showed that mildronate enhanced learning/memory formation that coincided with the proliferation of neural progenitor cells, changing/regulating of the expression of biomarker proteins which are involved in the activation of glutamatergic and cholinergic pathways, transcription factors and adhesion molecule. The data from our study suggest that mildronate may be useful as a possible cognitive enhancer for the treatment of patients with neurodegenerative diseases with dementia.
    Pharmacology Biochemistry and Behavior 03/2013; 106. DOI:10.1016/j.pbb.2013.03.012 · 2.82 Impact Factor